MorningSun: An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies

Condition: Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Richter's transformation, transformed follicular lymphoma

Go To Trial Homepage

For more information you may call clinical trials department directly at 732-390-7750 or email us at astera.clinicaltrial@asterahealthcare.org.